Literature DB >> 19134524

Lung transplant outcomes in white and African American recipients: special focus on acute and chronic rejection.

Rajiv Lingaraju1, Alberto Pochettino, Nancy P Blumenthal, James Mendez, James Lee, Jason D Christie, Robert M Kotloff, Vivek N Ahya, Denis Hadjiliadis.   

Abstract

BACKGROUND: The effects of lung transplant recipient race on post-transplant outcomes have not been adequately evaluated. This cohort study seeks to determine the characteristics of African American lung transplant recipients and the effects of African American race on post-transplant outcomes, particularly acute and chronic rejection, compared with white recipients, at a single center.
METHODS: There were 485 first-time lung transplantations (431 white, 47 African American, 5 Hispanic and 2 Asian recipients) performed at the University of Pennsylvania between 1991 and 2006. All white and African American recipients were compared based on pre-transplant diagnoses and post-transplant survival. The cohort from 1998 to 2006 (239 white and 25 African American recipients) was also compared based on acute rejection score (ARS) and development of bronchiolitis obliterans syndrome (BOS).
RESULTS: Chronic obstructive pulmonary disease was the most common diagnosis leading to lung transplantation in both groups, but sarcoidosis was a much more common indication in African American recipients (white, 1%; African American, 28%; p < 0.001). Survival was similar in the two groups (white vs African American groups: 1 month, 90.0% vs 87.2%; 1 year, 74.9% vs 74.5%; 5 years, 52.3% vs 50.5%, respectively; p = 0.84). Freedom from BOS at 3 years (white, 60.3%; African American, 62.8%; p = 0.30) and ARS per biopsy (white, 0.83 +/- 0.82; African American, 0.63 +/- 0.77; p = 0.31) were similar in both groups.
CONCLUSIONS: White and African American patients seek lung transplantation for different diseases, but post-transplant outcomes were found to be similar. Larger, multi-center studies are needed to confirm these results.

Entities:  

Mesh:

Year:  2008        PMID: 19134524     DOI: 10.1016/j.healun.2008.10.014

Source DB:  PubMed          Journal:  J Heart Lung Transplant        ISSN: 1053-2498            Impact factor:   10.247


  3 in total

1.  Response.

Authors:  Mehdi Mirsaeidi; Roberto F Machado; Dean Schraufnagel; Nadera J Sweiss; Robert P Baughman
Journal:  Chest       Date:  2015-02       Impact factor: 9.410

2.  Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation.

Authors:  Ramsey R Hachem; Roger D Yusen; Bryan F Meyers; Aviva A Aloush; Thalachallour Mohanakumar; G Alexander Patterson; Elbert P Trulock
Journal:  J Heart Lung Transplant       Date:  2010-06-16       Impact factor: 10.247

Review 3.  Clinical Presentations, Pathogenesis, and Therapy of Sarcoidosis: State of the Art.

Authors:  Francesca Polverino; Elisabetta Balestro; Paolo Spagnolo
Journal:  J Clin Med       Date:  2020-07-24       Impact factor: 4.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.